Overview

A Multicenter, Randomized, Double-blind, Three-arm, Parallel Clinical Endpoint Bioequivalence Study of Monometasone Furoate Nasal Spray in Patients With Seasonal Allergic Rhinitis

Status:
UNKNOWN

Trial end date:
2024-06-30

Target enrollment:

Participant gender:

Summary

Taking the mamsonic acid nasal spray held by Zhejiang Xianxian Pharmaceutical Technology Co., Ltd. as the test agent,Bannicate nose spray (product name: inside: insideSchuro®) is a reference preparation. Among the seasonal allergic rhinitis patients, through comparative clinical end, evaluation.The biological equivalent of the two types of branic acid Miimone pine nose spray agent. Observe the test agent and reference preparation in the season.Safety in patients with sexual allergic rhinitis.

Phase:

PHASE3

Details

Lead Sponsor:

Zheng Liu ENT

Collaborator:

Zhejiang Xianju Pharma Tech. Co., Ltd

Treatments:

Mometasone Furoate